ArticleJornal brasileiro de nefrologia
C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: a diagnostic and therapeutic challenge.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C3 glomerulopathy represents a heterogeneous group of glomerulopathies characterized by hyperactivity of the alternative complement pathway. Although the pathophysiology is incompletely understood, an association between this disease and monoclonal gammopathies is increasingly recognized, especially in older individuals. There is still some uncertainty regarding the best treatment for patients with monoclonal gammopathy-associated C3 glomerulopathy. However, recent evidence suggests that myeloma-targeted therapies are associated with improved renal outcomes compared with conservative or conventional immunosuppressive therapies. This case report describes the clinical course and long-term follow-up of a patient with monoclonal gammopathy-associated C3 glomerulonephritis treated with myeloma-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.